Bertrand Jordan – författare

Identification de l’ADN, développement du génie génétique, isolement des gènes responsables de maladies graves, décodage du génome humain : la génétique a ouvert d’immenses espoirs pour notre santé. Les thérapies géniques seraient-elles un mirage scientifique ?Bertrand Jordan raconte cette grande aventure : l’enthousiasme des scientifiques et les premières tentatives infructueuses, les obstacles et les difficultés techniques, le rôle très important de l’Association française contre les myopathies, les enfants bulles sauvés à l’hôpital Necker à Paris, les perspectives offertes par les cellules souches… Il explique l’engouement suscité et les perspectives qui s’offrent. Plus que jamais aujourd’hui la question se pose : va-t-on pouvoir remplacer les gènes défectueux de nos cellules pour guérir les maladies héréditaires, les cancers ou encore le sida ? L’ADN va-t-il devenir un médicament ?Bertrand Jordan, biologiste moléculaire, a été directeur de recherche au CNRS, directeur du Centre d’immunologie de Marseille- Luminy et coordinateur de Marseille-Nice Génopole.

Microarray technology has made strong progress over the past decade, and there have also been significant changes in application areas, from nucleic acids to proteomics and from research to clinical applications. This book provides a comprehensive overview of microarrays in diagnostics and biomarker development, covering DNA, peptide, protein and tissue arrays. The focus is on entities that are in actual clinical use, or quite close, and on recent developments, such as peptide and aptamer arrays. A further topic is the miniaturisation towards “nanoarrays”, which is expected to have great potential in clinical applications. Relevant issues of bioinformatics and statistical analysis of array data are discussed in detail, as well as the barriers to the commercialisation of array-based tests and the vexing IP issues involved. Thus, the book should be very useful tor active array users as well as to newcomers seeking to make the best choice between different technologies.

Microarray technology has made strong progress over the past decade, and there have also been significant changes in application areas, from nucleic acids to proteomics and from research to clinical applications. This book provides a comprehensive overview of microarrays in diagnostics and biomarker development, covering DNA, peptide, protein and tissue arrays. The focus is on entities that are in actual clinical use, or quite close, and on recent developments, such as peptide and aptamer arrays. A further topic is the miniaturisation towards “nanoarrays”, which is expected to have great potential in clinical applications. Relevant issues of bioinformatics and statistical analysis of array data are discussed in detail, as well as the barriers to the commercialisation of array-based tests and the vexing IP issues involved. Thus, the book should be very useful tor active array users as well as to newcomers seeking to make the best choice between different technologies.